在怀孕和产后严重高血压的生理治疗
Allison M Davis1, Christina T Blanchard, Akila Subramaniam
1Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, and the Center for Women's Reproductive Health, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Obstetrics and gynecology
|November 30, 2023
概括
孕妇和产后患者严重高血压的生理治疗需要更少的药物剂量. 这种方法显示出希望,尽管达到非严重血压的时间相似.
科学领域:
- 产科和妇科 产科和妇科
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在怀孕和分娩后的严重高血压带来了重大风险.
- 目前严重高血压的治疗策略可能并不总是与潜在的生理状态保持一致.
- 了解生理学和药物反应之间的相互作用对于优化护理至关重要.
研究的目的:
- 评估在孕妇和产后患者严重高血压的生理治疗方法的有效性.
- 为了比较接受生理治疗与非生理治疗的患者之间的结果.
主要方法:
- 对1120名患有严重高血压 (血压≥160/110毫米) 的孕妇和产后患者进行了回顾性队列研究.
- 根据高动力学 (脉冲压≥65mmHg) 或血管收缩性 (透气血压≥100mmHg) 生理学进行分类的患者.
- 生理治疗包括Labetalol用于高动态状态或Hydralazine用于血管收缩状态.
- 主要结局:抗高血压剂剂量的数量,以达到非严重的BP.
主要成果:
- 生理治疗与需要的抗高血压剂剂量数量的统计显著减少有关 (1.4对1.6剂量).
- 接受生理治疗的患者需要药物转换的几率较低 (2.5%与4.7%相比).
- 两组之间在达到非严重血压所需时间方面没有显著差异.
结论:
- 孕妇和产后患者的严重高血压的生理指导治疗可能会导致更有效的药物使用.
- 这种量身定制的方法显示了减少药物升级的潜力.
- 需要进一步的研究来验证这些发现,并探索更广泛的临床影响.
相关概念视频
01:33Hormonal Regulation
33.2K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.2K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
473
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
473